JP5687823B2 - 癌治療のための医薬品およびその使用 - Google Patents

癌治療のための医薬品およびその使用 Download PDF

Info

Publication number
JP5687823B2
JP5687823B2 JP2008550619A JP2008550619A JP5687823B2 JP 5687823 B2 JP5687823 B2 JP 5687823B2 JP 2008550619 A JP2008550619 A JP 2008550619A JP 2008550619 A JP2008550619 A JP 2008550619A JP 5687823 B2 JP5687823 B2 JP 5687823B2
Authority
JP
Japan
Prior art keywords
endostatin
seq
cancer
polyethylene glycol
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008550619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523743A (ja
Inventor
永章 ▲羅▼
永章 ▲羅▼
慶▼ ▲韓
慶▼ ▲韓
清新 雷
清新 雷
国▲棟▼ 常
国▲棟▼ 常
彦 付
彦 付
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protgen Ltd
Original Assignee
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protgen Ltd filed Critical Protgen Ltd
Publication of JP2009523743A publication Critical patent/JP2009523743A/ja
Application granted granted Critical
Publication of JP5687823B2 publication Critical patent/JP5687823B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008550619A 2006-01-20 2007-01-19 癌治療のための医薬品およびその使用 Expired - Fee Related JP5687823B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB2006100112479A CN100475270C (zh) 2006-01-20 2006-01-20 一种治疗肿瘤的药物及其应用
CN200610011247.9 2006-01-20
PCT/CN2007/000204 WO2007082483A1 (en) 2006-01-20 2007-01-19 Medicament for treatment of tumor and the use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013036487A Division JP2013163674A (ja) 2006-01-20 2013-02-26 癌治療のための医薬品およびその使用

Publications (2)

Publication Number Publication Date
JP2009523743A JP2009523743A (ja) 2009-06-25
JP5687823B2 true JP5687823B2 (ja) 2015-03-25

Family

ID=38287273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008550619A Expired - Fee Related JP5687823B2 (ja) 2006-01-20 2007-01-19 癌治療のための医薬品およびその使用
JP2013036487A Pending JP2013163674A (ja) 2006-01-20 2013-02-26 癌治療のための医薬品およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013036487A Pending JP2013163674A (ja) 2006-01-20 2013-02-26 癌治療のための医薬品およびその使用

Country Status (8)

Country Link
US (2) US20100285103A1 (enExample)
EP (1) EP1985302B1 (enExample)
JP (2) JP5687823B2 (enExample)
CN (3) CN100475270C (enExample)
AU (1) AU2007207268B2 (enExample)
CA (1) CA2637698C (enExample)
NO (1) NO20083287L (enExample)
WO (1) WO2007082483A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101381413A (zh) * 2007-09-05 2009-03-11 江苏先声药物研究有限公司 一种修饰的重组人内皮抑素及其应用
CN101396347B (zh) * 2007-09-27 2011-12-14 江苏先声药物研究有限公司 一种重组人血管内皮抑制素缓释微球的制备方法
CN101265298B (zh) * 2008-04-30 2011-11-09 中国药科大学 含有非天然氨基酸的内皮抑素突变体及其衍生物
CN101642559B (zh) * 2008-06-30 2012-08-01 江苏先声药物研究有限公司 含微粉化人血管内皮抑制素的药物组合物
WO2011050311A1 (en) 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
JP2013523726A (ja) * 2010-04-01 2013-06-17 オンコレナ エービー 腎細胞癌の改良された治療
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
RU2014113924A (ru) * 2011-09-09 2015-10-20 Тсинхуа Юниверсити Мутанты эндостатина с мутациями в сайтах связывания атф
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN104031261B (zh) * 2014-06-20 2017-10-27 电子科技大学 温敏性共聚物及其水凝胶体系
CN104174015A (zh) * 2014-08-22 2014-12-03 广州安辰医药科技有限公司 疫苗组合物及其在肿瘤治疗中的用途
CN104515768B (zh) * 2014-08-29 2017-01-25 湖南新大陆生物技术有限公司 一种肿瘤特异性生长因子检测试剂盒
CN104771603B (zh) * 2015-04-17 2018-05-18 张坤镛 一种改善唾液酸异常的中药口服药及制备方法
CN106924752B (zh) * 2015-12-30 2021-11-09 北京大学 制备蛋白质-聚氨基酸偶联物的方法
CN105646701B (zh) * 2016-03-29 2019-03-05 徐根兴 不同氨基酸结构的重组人内皮抑素蛋白及其制备方法和应用
CN107865824B (zh) * 2016-09-28 2020-04-03 山东先声生物制药有限公司 一种稳定的重组人血管内皮抑制素皮下注射组合物
AU2017357327B2 (en) * 2016-11-10 2023-04-06 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
US20200237796A1 (en) * 2017-07-30 2020-07-30 Tsinghua University Medication for inhibiting dna-pkcs
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用
CN117460533A (zh) * 2021-01-26 2024-01-26 清华大学 血管内皮抑制素在治疗和预防冠状病毒相关疾病中的应用
CN113350576A (zh) * 2021-05-21 2021-09-07 上海大学 快慢交联互补的双网络自愈合可注射水凝胶及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2002502826A (ja) 1998-02-09 2002-01-29 アヴェンティス ファーマシューティカルズ プロダクツ インコーポレイテッド Ｈｉｖ感染の治療用組成物および方法
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
ES2185595T5 (es) 1999-05-17 2009-12-17 Conjuchem Biotechnologies Inc. Peptidos antivirales modificados y sus composiciones para la prevencion y/o el tratamiento de infecciones viricas.
WO2001017614A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
KR20040004449A (ko) * 2000-11-28 2004-01-13 휘닉스 파머컬러직스, 인크. 변형된 아르기닌 데이미나제
EP1401480B1 (en) * 2001-02-22 2012-11-28 Novartis AG Viral vectors encoding endostatin in the treatment of ocular neovascularization
NZ534310A (en) * 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
NZ537493A (en) * 2002-07-24 2007-05-31 Hoffmann La Roche Pegylated T1249 polypeptide
AU2003258675B2 (en) * 2002-08-28 2009-03-26 Novartis Ag Ocular gene therapy
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
WO2004076474A2 (en) 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
JP2007529410A (ja) * 2003-08-29 2007-10-25 チルドレンズ メディカル センター コーポレーション 子宮内膜症を治療又は防止するためのペプチド
DK1682583T3 (da) 2003-11-13 2012-05-07 Hanmi Holdings Co Ltd Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
CN100355784C (zh) 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja) 2004-03-03 2005-09-15 Nipro Corp 血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1311867C (zh) 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Also Published As

Publication number Publication date
JP2009523743A (ja) 2009-06-25
CN101405019A (zh) 2009-04-08
AU2007207268B2 (en) 2011-08-18
EP1985302A4 (en) 2013-01-02
AU2007207268A1 (en) 2007-07-26
CN101405019B (zh) 2014-06-04
CN104043107B (zh) 2016-09-07
CA2637698A1 (en) 2007-07-26
JP2013163674A (ja) 2013-08-22
WO2007082483A1 (en) 2007-07-26
CN100475270C (zh) 2009-04-08
EP1985302B1 (en) 2018-01-03
WO2007082483B1 (en) 2007-09-07
NO20083287L (no) 2008-10-20
US20180360922A1 (en) 2018-12-20
EP1985302A1 (en) 2008-10-29
CN101002946A (zh) 2007-07-25
CA2637698C (en) 2016-09-20
CN104043107A (zh) 2014-09-17
US20100285103A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
JP5687823B2 (ja) 癌治療のための医薬品およびその使用
CA2675231C (en) A conjugate comprising angiostatin or its fragment, the method for producing the conjugate and use thereof
JP2009523433A (ja) 癌治療のための新規複合体
JP7140454B2 (ja) ペグ化エンドスタチン類似体およびその適用
CN101596320B (zh) 一种治疗肿瘤的药物及其应用
HK1122498A (en) Medicament for treatment of tumor and the use thereof
AU2012203658B2 (en) Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
HK1122498B (en) Medicament for treatment of tumor and the use thereof
CN103083681A (zh) 一种治疗肿瘤的药物及其应用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120502

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150123

R150 Certificate of patent or registration of utility model

Ref document number: 5687823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees